Long-Term Safety of Tolvaptan in ADPKD Where Do We Stand?

被引：4
作者：
Patel, Dipal M. [1 ]
Dahl, Neera K. [1 ]
机构：
[1] Yale Univ, Dept Internal Med, Nephrol Sect, New Haven, CT USA
来源：
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2021年 / 16卷 / 01期
关键词：
ADPKD; safety; clinical trial; Tolvaptan; autosomal dominant polycystic kidney disease;
D O I：
10.2215/CJN.17981120
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3 / 5
页数：3
相关论文
共 10 条
  • [1] Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan
    Anderegg, Manuel A.
    Dhayat, Nasser A.
    Sommer, Grit
    Semmo, Mariam
    Huynh-Do, Uyen
    Vogt, Bruno
    Fuster, Daniel G.
    [J]. KIDNEY MEDICINE, 2020, 2 (02) : 162 - 171
  • [2] A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
    Chebib, Fouad T.
    Perrone, Ronald D.
    Chapman, Arlene B.
    Dahl, Neera K.
    Harris, Peter C.
    Mrug, Michal
    Mustafa, Reem A.
    Rastogi, Anjay
    Watnick, Terry
    Yu, Alan S. L.
    Torres, Vicente E.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 29 (10): : 2458 - 2470
  • [3] Autosomal dominant polycystic kidney disease
    Cornec-Le Gall, Emilie
    Alam, Ahsan
    Perrone, Ronald D.
    [J]. LANCET, 2019, 393 (10174) : 919 - 935
  • [4] Role of Liver Transplantation in Tolvaptan-Associated Acute Liver Failure
    Endo, Mayumi
    Katayama, Kan
    Matsuo, Hiroshi
    Horiike, Shinichiro
    Nomura, Shinsuke
    Hayashi, Akinobu
    Ishikawa, Eiji
    Harada, Tetsuro
    Sugimoto, Ryosuke
    Tanemura, Akihiro
    Sugimoto, Kazushi
    Isaji, Shuji
    Ito, Masaaki
    [J]. KIDNEY INTERNATIONAL REPORTS, 2019, 4 (11): : 1653 - 1657
  • [5] A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials
    Shoaf, Susan E.
    Ouyang, John
    Sergeyeva, Olga
    Estilo, Alvin
    Li, Hui
    Leung, Deborah
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (05): : 643 - 650
  • [6] Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
    Torres, Vicente E.
    Chapman, Arlene B.
    Devuyst, Olivier
    Gansevoort, Ron T.
    Perrone, Ronald D.
    Lee, Jennifer
    Hoke, Molly E.
    Estilo, Alvin
    Sergeyeva, Olga
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 16 (01): : 48 - 58
  • [7] Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
    Torres, Vicente E.
    Chapman, Arlene B.
    Devuyst, Olivier
    Gansevoort, Ron T.
    Perrone, Ronald D.
    Koch, Gary
    Ouyang, John
    McQuade, Robert D.
    Blais, Jaime D.
    Czerwiec, Frank S.
    Sergeyeva, Olga
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) : 1930 - 1942
  • [8] Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial (vol 32, 2017)
    Torres, Vicente E.
    Chapman, Arlene B.
    Devuyst, Olivier
    Gansevoort, Ron T.
    Perrone, Ronald D.
    Dandurand, Ann
    Ouyang, John
    Czerwiec, Frank S.
    Blais, Jaime D.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (07) : 1262 - 1262
  • [9] Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
    Torres, Vicente E.
    Chapman, Arlene B.
    Devuyst, Olivier
    Gansevoort, Ron T.
    Grantham, Jared J.
    Higashihara, Eiji
    Perrone, Ronald D.
    Krasa, Holly B.
    Ouyang, John
    Czerwiec, Frank S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (25) : 2407 - 2418
  • [10] Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
    Watkins, Paul B.
    Lewis, James H.
    Kaplowitz, Neil
    Alpers, David H.
    Blais, Jaime D.
    Smotzer, Dan M.
    Krasa, Holly
    Ouyang, John
    Torres, Vicente E.
    Czerwiec, Frank S.
    Zimmer, Christopher A.
    [J]. DRUG SAFETY, 2015, 38 (11) : 1103 - 1113
1